Scientific Reports (Oct 2022)

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

  • Baoshan Zhang,
  • Deepika Gollapudi,
  • Jason Gorman,
  • Sijy O’Dell,
  • Leland F. Damron,
  • Krisha McKee,
  • Mangaiarkarasi Asokan,
  • Eun Sung Yang,
  • Amarendra Pegu,
  • Bob C. Lin,
  • Cara W. Chao,
  • Xuejun Chen,
  • Lucio Gama,
  • Vera B. Ivleva,
  • William H. Law,
  • Cuiping Liu,
  • Mark K. Louder,
  • Stephen D. Schmidt,
  • Chen-Hsiang Shen,
  • Wei Shi,
  • Judith A. Stein,
  • Michael S. Seaman,
  • Adrian B. McDermott,
  • Kevin Carlton,
  • John R. Mascola,
  • Peter D. Kwong,
  • Q. Paula Lei,
  • Nicole A. Doria-Rose

DOI
https://doi.org/10.1038/s41598-022-22435-2
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Abstract The broadly neutralizing antibody (bNAb) CAP256-VRC26.25 has exceptional potency against HIV-1 and has been considered for clinical use. During the characterization and production of this bNAb, we observed several unusual features. First, the antibody appeared to adhere to pipette tips, requiring tips to be changed during serial dilution to accurately measure potency. Second, during production scale-up, proteolytic cleavage was discovered to target an extended heavy chain loop, which was attributed to a protease in spent medium from 2-week culture. To enable large scale production, we altered the site of cleavage via a single amino acid change, K100mA. The resultant antibody retained potency and breadth while avoiding protease cleavage. We also added the half-life extending mutation LS, which improved the in vivo persistence in animal models, but did not impact neutralization activity; we observed the same preservation of neutralization for bNAbs VRC01, N6, and PGDM1400 with LS on a 208-virus panel. The final engineered antibody, CAP256V2LS, retained the extraordinary neutralization potency of the parental antibody, had a favorable pharmacokinetic profile in animal models, and was negative in in vitro assessment of autoreactivity. CAP256V2LS has the requisite potency, developability and suitability for scale-up, allowing its advancement as a clinical candidate.